-
公开(公告)号：US20190195895A1
公开(公告)日：2019-06-27
申请号：US16241985
申请日：2019-01-07
CPC分类号： G01N33/74 , A61K38/22 , A61K38/24 , G01N33/6893 , G01N2333/575 , G01N2800/368 , G01N2800/52
摘要： Method of diagnosis of IVF viability. The method includes ascertaining a subject's AMH level from testing and then selecting one pregnancy or live birth prognosis category that applies to the ascertained AMH level by matching the ascertained AMH level with an applicable one of a plurality of ranges of AMH levels pertaining to an age of the subject. The matching indicates the prognosis category that applies, i.e., (that is, good, intermediate or poor. In view of the diagnosis, a method of administration of AMH may be pursued to increase probability of pregnancy or live birth chances. Alternatively, the administration of AMH may be at AMH levels that will terminate pregnancy or increase the chance of miscarriage.
-
公开(公告)号：US20190192633A1
公开(公告)日：2019-06-27
申请号：US16114002
申请日：2018-08-27
申请人： Neuralight HD, LLC
CPC分类号： A61K38/24 , A61K9/0019 , A61K9/08 , A61K9/19
摘要： Depression and PTSD are treated by administration of hCG, or an hCG analog, or a prodrug or metabolite of hCG or an hCG analog, in an amount equivalent to a subcutaneous dose of 50-200 IU, preferably 120-170 IU, more preferably 140-160 IU, of hCG per day.
-
3.发明申请公开(公告)号：US20190183963A1
公开(公告)日：2019-06-20
申请号：US16042756
申请日：2018-07-23
申请人： Thorn BioScience LLC
发明人： James W. Lauderdale
CPC分类号： A61K38/09 , A61D19/02 , A61K9/0019 , A61K9/0034 , A61K9/06 , A61K9/08 , A61K9/10 , A61K38/24
摘要： A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.
-
公开(公告)号：US20180326082A1
公开(公告)日：2018-11-15
申请号：US15852581
申请日：2017-12-22
申请人： Genzyme Corporation
发明人： Clark PAN , Huawei QIU , Sunghae PARK
摘要： Described herein are compositions of Thyroid Stimulating Hormone (TSH), wherein at least one polyalkylene glycol polymer is attached to a carbohydrate site of the TSH. Also described are compositions of mutated Thyroid Stimulating Hormone (TSH) and at least one polyalkylene glycol polymer, wherein the mutated TSH comprises a TSH in which one or more amino acid residues has been substituted with cysteine residue, and the polyalkylene glycol polymer is attached to the mutated TSH at the site of the substituted cysteine residue. Pharmaceutical compositions comprising these TSH compositions and method of treating a thyroid condition in a patient in need thereof, by administering to the patient an effective amount of the pharmaceutical compositions are also described.
-
公开(公告)号：US20180303944A1
公开(公告)日：2018-10-25
申请号：US15984261
申请日：2018-05-18
发明人： Oleh Taratula , Canan Schumann , Olena Taratula , Adam W.G. Alani
IPC分类号： A61K47/34 , A61K48/00 , A61K31/7105 , C08L77/04 , A61K9/00
CPC分类号： A61K47/34 , A61K9/0019 , A61K31/7105 , A61K38/16 , A61K38/24 , A61K45/06 , A61K47/00 , A61K48/0058 , A61P21/00 , C07K14/473 , C08L77/04 , C08L2203/02
摘要： mRNA polymer complexes and drug delivery systems are disclosed herein that include a cationic polymer electrostatically complexed to an mRNA molecule that encodes a desired protein. Also disclosed herein are methods of treating as well as methods of slowing the loss of, increasing, and/or maintaining lean muscle mass in a subject, such as using mRNA polymer complexes and drug delivery systems.
-
公开(公告)号：US20180264086A1
公开(公告)日：2018-09-20
申请号：US15760846
申请日：2016-09-16
申请人： Glycotope GmbH
发明人： Steffen Goletz , Lars Stoeckl
CPC分类号： A61K38/24 , A61K9/0019 , A61K47/10 , A61K47/183 , A61P15/08
摘要： The present invention pertains to the field of gonadotropins. In particular, an improved composition comprising recombinant human follicle-stimulating hormone and chlorocresol is provided. This improved composition has an increased stability at high temperatures and is useful in the treatment of infertility, in particular in human patients.
-
公开(公告)号：US10010565B2
公开(公告)日：2018-07-03
申请号：US14364286
申请日：2012-12-14
发明人： Yuan Cheng , Aaron J. W. Hsueh , Yorino Sato
CPC分类号： A61K35/54 , A61K38/16 , A61K38/1703 , A61K38/22 , A61K38/2242 , A61K38/24 , A61K39/39533 , C12N5/0609 , C12N2501/30 , C12N2501/415 , C12N2501/998 , C12N2517/10
摘要： Methods are provided for stimulating ovarian preantral and antral follicles in a mammal.
-
公开(公告)号：US09987359B2
公开(公告)日：2018-06-05
申请号：US14907165
申请日：2014-05-23
发明人： Koji Kimura , Shuichi Matsuyama , Kenyo Ishii , Makoto Seki , Toshiya Hamada
CPC分类号： A61K47/02 , A61K9/0019 , A61K35/02 , A61K38/24
摘要： The present invention provides a subcutaneous injection product for cattle for inducing superovulation characterized by comprising aluminum hydroxide gel and an efficient amount of a gonadotropin, wherein the concentration of the aluminum hydroxide is, in terms of the amount of aluminum, higher than or equal to 0.2 mg/mL and lower than 1.0 mg/mL, which is a subcutaneous injection product that is useful for producing good calves and that can induce superovulation in a cow by a single administration. The present invention also provides a method for producing good calves undergoing steps of subcutaneously injecting the aforementioned injection product into a cow to thereby induce superovulation, inducing estrus in the cow, conducting artificial insemination, and then collecting fertilized eggs.
-
公开(公告)号：US09956164B2
公开(公告)日：2018-05-01
申请号：US15304677
申请日：2015-04-16
申请人： Veyx-Pharma GmbH
CPC分类号： A61K9/0002 , A61K9/0019 , A61K9/0024 , A61K9/10 , A61K38/09 , A61K38/24 , A61K47/14 , A61K47/44
摘要： A veterinary pharmaceutical composition, including at least one active veterinary pharmaceutical substance which is selected among gonadorelin and gonadorelin analogs as well as salts of gonadorelin and of the gonadorelin analogs, is provided. The composition includes a liposome-free matrix which delays the release of the active veterinary pharmaceutical substance from the composition, which matrix includes a basic material which is selected from the group consisting of natural and synthetic triglycerides, vegetable oils, diacylpropanediols, diacylbutanediols and mixtures of these substances, the veterinary pharmaceutical composition including no biodegradable polymer.
-
公开(公告)号：US20170348231A1
公开(公告)日：2017-12-07
申请号：US15171630
申请日：2016-06-02
申请人： NHTherapeutics INC
摘要： Provided herein is an optimized method of enhancing endogenous gonadotropins and testosterone/estrogen production and concentrations comprising administration of a therapeutically effective amount of at least one GnRH agonist to a patient in need of such treatment. A method and dosing regimen is also described for delivery across the mucosa of the oral cavity for maximizing absorption and delivery, limiting systemic exposure and unwanted side effects, effectuating a sustained increase in concentrations of sex hormones and providing a non-invasive delivery that does not require inpatient visits. The method described benefits conditions such as hypogonadism in men due to aging or disease and symptoms related to menopause in women.
-
-
-
-
-
-
-
-
-
搜索结果
631 条记录 (耗时 0.027 秒)